Longeveron Inc. (LGVN)
- GlobeNewswire
Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
MIAMI, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the 3rd Annual ROTH Healthcare Opportunities Conference taking place October 9, 2024 in New York City, including Wa’el Hashad, Chief Executive Officer, speaking on the panel “Emerging Frontiers in Neuroscience” and investor 1x1 meeti
- GlobeNewswire
Longeveron to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa
Exploring potential partnership and strategic opportunities for the Company’s cellular therapy program in Alzheimer’s diseaseHighlighting the Company’s cellular therapy contract development and manufacturing business at its 15,000 square feet facility with 8 current Good Manufacturing Practice (cGMP) cleanroom suites MIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threate
- GlobeNewswire
Longeveron® Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B™ in Hypoplastic Left Heart Syndrome (HLHS)
Wa'el Hashad Wa'el Hashad, CEO, Longeveron On-going Phase 2b clinical trial (ELPIS II) deemed pivotal and, if positive, acceptable for Biological License Application (BLA) submission for potential full traditional approvalAlignment with FDA on ELPIS II primary and secondary endpointsAlignment with FDA on CMC and Potency Assay plan and requirements MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cell
